Cargando…

Recent Advances and Future Perspectives in Polymer-Based Nanovaccines

Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Pippa, Natassa, Gazouli, Maria, Pispas, Stergios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226647/
https://www.ncbi.nlm.nih.gov/pubmed/34073648
http://dx.doi.org/10.3390/vaccines9060558
_version_ 1783712336660398080
author Pippa, Natassa
Gazouli, Maria
Pispas, Stergios
author_facet Pippa, Natassa
Gazouli, Maria
Pispas, Stergios
author_sort Pippa, Natassa
collection PubMed
description Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Novel technologies such as nanoparticulate systems and adjuvants can enable safe and effective vaccines for difficult target populations such as newborns, elderly, and the immune-compromised. More recently, polymer-based particles have found application as vaccine platforms and vaccine adjuvants due to their ability to prevent antigen degradation and clearance, coupled with enhanced uptake by professional antigen-presenting cells (APCs). Polymeric nanoparticles have been applied in vaccine delivery, showing significant adjuvant effects as they can easily be taken up by APCs. In other words, polymer-based systems offer a lot of advantages, including versatility and flexibility in the design process, the ability to incorporate a range of immunomodulators/antigens, mimicking infection in different ways, and acting as a depot, thereby persisting long enough to generate adaptive immune responses. The aim of this review is to summarize the properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as the process of their development by the pharmaceutical industry.
format Online
Article
Text
id pubmed-8226647
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82266472021-06-26 Recent Advances and Future Perspectives in Polymer-Based Nanovaccines Pippa, Natassa Gazouli, Maria Pispas, Stergios Vaccines (Basel) Review Vaccination is the most valuable and cost-effective health measure to prevent and control the spread of infectious diseases. A significant number of infectious diseases and chronic disorders are still not preventable by existing vaccination schemes; therefore, new-generation vaccines are needed. Novel technologies such as nanoparticulate systems and adjuvants can enable safe and effective vaccines for difficult target populations such as newborns, elderly, and the immune-compromised. More recently, polymer-based particles have found application as vaccine platforms and vaccine adjuvants due to their ability to prevent antigen degradation and clearance, coupled with enhanced uptake by professional antigen-presenting cells (APCs). Polymeric nanoparticles have been applied in vaccine delivery, showing significant adjuvant effects as they can easily be taken up by APCs. In other words, polymer-based systems offer a lot of advantages, including versatility and flexibility in the design process, the ability to incorporate a range of immunomodulators/antigens, mimicking infection in different ways, and acting as a depot, thereby persisting long enough to generate adaptive immune responses. The aim of this review is to summarize the properties, the characteristics, the added value, and the limitations of the polymer-based nanovaccines, as well as the process of their development by the pharmaceutical industry. MDPI 2021-05-26 /pmc/articles/PMC8226647/ /pubmed/34073648 http://dx.doi.org/10.3390/vaccines9060558 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pippa, Natassa
Gazouli, Maria
Pispas, Stergios
Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title_full Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title_fullStr Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title_full_unstemmed Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title_short Recent Advances and Future Perspectives in Polymer-Based Nanovaccines
title_sort recent advances and future perspectives in polymer-based nanovaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226647/
https://www.ncbi.nlm.nih.gov/pubmed/34073648
http://dx.doi.org/10.3390/vaccines9060558
work_keys_str_mv AT pippanatassa recentadvancesandfutureperspectivesinpolymerbasednanovaccines
AT gazoulimaria recentadvancesandfutureperspectivesinpolymerbasednanovaccines
AT pispasstergios recentadvancesandfutureperspectivesinpolymerbasednanovaccines